Vaccine Therapy in Treating Patients With Liver Cancer

Inclusion Criteria: * HLA-A\*0201 positive adults over the age of 18. * Have HCC with a serum AFP determination \>30ng/ml. * Both male and female patients may be enrolled. * Karnofsky Performance Status greater than or equal to 70 percent. * No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease. * No previous evidence of opportunistic infection. * Adequate baseline hematological function as assessed by the following laboratory values with 30 days prior to study entry: 1. Hemoglobin \>9.0g/dl 2. Platelets \>50000/mm3 3. Absolute Neutrophil Count \>1,000/mm3 * Child-Pugh Class A or B for chronic liver disease. * Ability to give informed consent. Exclusion Criteria: * Any congenital or acquired condition leading to inability to generate an immune response, including concomitant immune suppressive therapy. * Concomitant steroid therapy or chemotherapy, or any of these other treatments \< 30 days before the first vaccination. * Females of child-bearing potential must have negative serum beta-HCG pregnancy test (within Day -14 to Day 0). * Acute infection: any acute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed within 14 days prior to study treatment. * HIV-infected patients. * Patients with any underlying conditions which would contraindicate therapy with study treatment. * Patients with organ allografts. * O2 sat \<91% on room air; dyspnea at rest.